

**Stem Cell Transplantation for Autoimmune Diseases  
EBMT's Autoimmune Diseases Working Party Educational Meeting 2019**



**DATE:** 31st October – 1st November

**CITY:** Berlin

**COUNTRY:** Germany  
Kaiserin-Friedrich Haus

**VENUE:** Robert-Koch-Platz 7  
10115 Berlin

**LOCAL ORGANIZERS:** Tobias Alexander, Renate Arnold, Falk Hiepe

**ADWP:** John Snowden, Tobias Alexander, Manuela Badoglio, Helen Jessop

## Thursday 31<sup>st</sup> October 2019

<b>12:00</b>	<b>Arrival</b>	
<b>12:30</b>	<b>Welcome (Lecture Hall)</b>  <b>Introduction</b> Evolution of HSCT to evidence-based therapy	<b>Renate Arnold, Tobias Alexander, John Snowden, Helen Jessop (on behalf of the EBMT Nurses Group)</b>  John Snowden (Sheffield)
<b>13:00-14:30</b>	<b>Scientific Session: Immunologic mechanisms and the microbiome (Lecture Hall)</b> (20 minutes + 10 minutes discussion)  Autoreactive memory drives persistent inflammation in AD  Reset of autoimmunity into self-tolerant state with HSCT  Interaction of microbiota and HSCT, and how this may influence immune responses in AD	<b>Gerd Burmester, Britta Siegmund</b>  Andreas Radbruch (Berlin)  Paolo Muraro (London)  Ernst Holler (Regensburg)
<b>13:00-14:30</b>	<b>Nurses Parallel Session (Gallery)</b> (10 minutes + 5 minutes discussion)  Information and supportive care management in a) MS b) Rheumatic diseases c) Crohn's disease d) Patients going and returning from overseas	<b>Helen Jessop</b>  Claudia Boglione (Florence) Tina Hansmann and Birgit Jung (Tübingen) Ariadna Domenec (Barcelona) Helen Jessop (Sheffield)
<b>14:30-16:00</b>	<b>Conditioning regimen in HSCT for autoimmune diseases: how can we adapt it to improve outcomes? (Lecture Hall)</b> (20 minutes + 5 minutes discussion)  Toward a cure for severe scleroderma: HSCT regimens and outcome measurements  Adapting transplant technique to disease-specific requirements in autologous HSCT: Modifying the Non-myeloablative approach  Post-transplant Cyclophosphamide: a means of enhancing tolerance? (15 min + 5 min discussion)  Fertility and gonadal following HSCT for autoimmune diseases (15 min + 5 min discussion)	<b>Riccardo Saccardi, Tobias Alexander</b>  Keith Sullivan (Durham)  Richard Burt (Chicago)  Raffaella Greco (Milan)  Nina Salooja (London)
<b>16:00-16:30</b>	<b>Tea/Coffee</b>	
<b>16:30-18:00</b>	<b>Cell therapy (Lecture Hall)</b> (20 minutes + 10 minutes discussion)  CAR T-cells: Challenges and opportunities in AD  Supportive care in CAR T-cell therapy  Adoptive T-cell transfer for infection prophylaxis and relapse prevention	<b>John Snowden, Renate Arnold</b>  Stefan Miltenyi (Bergisch-Gladbach, Miltenyi Biotec) TBC (Gilead) Hermann Einsele (Würzburg)
<b>19:00</b>	<b>Dinner</b>	

## Friday 1<sup>st</sup> November 2019

<b>08:30-10:00</b>	<b>State-of-the-art for autologous HSCT in autoimmune diseases (Lecture Hall)</b> (15 minutes + 5 minutes discussion)  HSCT in Systemic Sclerosis HSCT in Multiple Sclerosis HSCT in Crohn's Disease HSCT for IDDM and other rare AD indications	<b>John Snowden, Renate Arnold</b>   Dominique Farge (Paris) Riccardo Saccardi (Firenze) Montserrat Rovira (Barcelona) Maria Carolina Oliveira (Ribeirão Preto)
<b>10:00-10:30</b>	<b>Tea/Coffee</b>	
<b>10:30-12:00</b>	<b>Parallel Session I: Neurology (Lecture Hall)</b> (10 minutes + 10 minutes discussion)  Conventional treatment of refractory MS Moscow experience of HSCT in MS EBMT Guidelines for HSCT in MS and other neurological diseases Prospective transplantation studies in MS	<b>Riccardo Saccardi, Joachim Burman</b>   Christoph Heesen (Hamburg) DA Federenko (Moscow) Basil Sharrack (Sheffield)  Lars Bø for RAM-MS trial (Bergen)
<b>10:30-12:00</b>	<b>Parallel Session II: Rheumatology (Terrace Room)</b> (10 minutes + 10 minutes discussion)  HSCT in SLE and other rheumatic diseases Patient selection in SSc Maintenance therapy in SSc Immunological studies and biomarkers	<b>Falk Hiepe, Joerg Henes</b>   Tobias Alexander (Berlin) Jeska de Vries-Bouwstra (Leiden) Nicoletta del Papa (Milano) Keith Sullivan (Duke)
<b>10:30-12:00</b>	<b>Parallel Session III: Gastroenterology (Library)</b> (10 minutes + 10 minutes discussion)  Update on conventional approaches to Crohn's disease and ulcerative colitis: where may HSCT have a role? ASTICLight - trial update Experience of allogeneic HSCT in CD Mucosal microRNA profiles and response to HSCT	<b>Chris Hawkey, Majid Kazmi</b>   Chris Hawkey (Nottingham)  J Snowden (Sheffield) & G Pockley (Nottingham) Richard Burt (Chicago) Amy Lewis (London)
<b>12:00-13:00</b>	<b>Lunch Symposium (Mallinckrodt)</b>  Extracorporeal photopheresis (ECP) – Indications and mode-of-action	<b>Tobias Alexander</b>
<b>13:00-14:30</b>	<b>'Cross-fertilisations' Session (Lecture Hall)</b> (15 minutes + 5 minutes discussion)  Chemotherapy and ATG: real life 'exposure' versus 'dose'. Could it affect outcomes of HSCT in autoimmune diseases?  HSCT for paediatric ADs, including monogenic autoimmune and autoinflammatory diseases  Allogeneic HSCT for adrenoleukodystrophy; what lessons can we learn for HSCT in autoimmune diseases  Late effects of HSCT in autoimmune diseases  <b>Closing remarks</b>	<b>John Snowden, Lars Bullinger</b>   Jürgen Kuball (Utrecht)  Arjan Lankester (Leiden, IEWP Chair)  Joern-Sven Kuehl (Leipzig)  Kirill Kirgizov (Moscow)  <b>Falk Hiepe, John Snowden, Helen Jessop (on behalf of the EBMT Nurses Group)</b>
<b>14:30-16:00</b>	<b>Business Meeting (Gallery)</b>	